Magnesium and Fibromyalgia: A Literature Review

Michael Boulis1*, Mary Boulis1*, and Daniel Clauw2

Abstract
Fibromyalgia, a widespread chronic pain disorder, imposes a multitude of hardships on patients and their communities. Supplements, specifically magnesium supplements, have been widely used by fibromyalgia patients in an attempt to control their symptoms. The aim of this work is to investigate if the widespread use of magnesium in fibromyalgia is supported by evidence in the literature. This review provides a layout of the studies examining the correlation between body magnesium levels and fibromyalgia. Furthermore, it elaborates on the trials testing the effectiveness of magnesium in treating different clinical parameters of fibromyalgia.

Keywords
fibromyalgia, pain, chronic pain, magnesium, supplements, literature review

Introduction
The term fibromyalgia is derived from the Latin “fibra,” meaning fibrous tissues; the Greek “mys,” meaning muscles; and “algia,” meaning pain. It is a complex widespread pain disorder. Pain is considered widespread when it involves both sides of the body, above and below the waist, and along the axial skeleton. Fibromyalgia is often associated with sleep difficulties, memory impairment, mood disturbance, irritable bowel syndrome, and fatigue.

Fibromyalgia is a chronic pain disorder. It is the third most common rheumatic disorder after low back pain and osteoarthritis. Fibromyalgia exhibits an immense burden at the individual and the society levels. Daily living activities of an individual can be profoundly impacted by fibromyalgia. Medical and pharmaceutical claims along with the annual total medical costs are significantly greater among fibromyalgia claimants than the overall population. High disability rates have been associated with fibromyalgia. Due to the healthcare costs along with the loss of productivity and work, fibromyalgia poses a significant social strain.

The underlying etiology for fibromyalgia remains obscure. While genetic and hormonal factors among others are thought to play a role in fibromyalgia patients, central sensitization is considered to be the main mechanism. Magnesium is known to play an important role in the prevention of central sensitization by blocking N-methyl-D-aspartate (NMDA) receptors in a voltage-dependent manner. Magnesium deficiency has been largely associated with muscle pain along with fatigue, sleep difficulties, and anxiety; all of which are common symptoms of fibromyalgia. In some studies, it is thought that magnesium deficiency, through reductions in muscle ATP levels, may play a role in the development of fibromyalgia. Other studies correlate increased levels of substance P (a neurotransmitter known for its role in pain perception) with magnesium deficiency as well as pain intensity in fibromyalgia, raising the question of a possible correlation between magnesium deficiency and fibromyalgia. While some estimates suggest that about half of the population in the United States consume inadequate amounts of magnesium, studies have shown that magnesium is one of the most widely used supplements by fibromyalgia patients. At the Mayo Clinic fibromyalgia treatment program, 2 studies (years 2003, 2017) were performed to evaluate the frequency and pattern of complementary and alternative medicine (CAM) use in fibromyalgia patients. Both studies found that magnesium was one of
Journal of Primary Care & Community Health

the most frequently used supplements in fibromyalgia. This review aims to explore and summarize the possible relationship between magnesium and fibromyalgia in the literature and hence determine the validity of magnesium use in fibromyalgia.

Materials and Methods

We searched the medical literature through Cochrane and PubMed databases using the terms “fibromyalgia” and “magnesium.” The search covered published articles through December 31, 2020. Bibliographies of relevant articles were searched as well. Inclusion criteria were articles written in English language that investigated a form of correlation between magnesium and fibromyalgia; the effect of magnesium on clinical parameters of fibromyalgia.

Results

A total of 18 relevant articles that met the inclusion criteria were found (Figure 1). These articles covered 2 main aspects: the correlation between magnesium levels in the body and fibromyalgia; the effect of magnesium supplementation on clinical parameters of fibromyalgia.

Studies Exploring the Correlation Between Magnesium Levels and Fibromyalgia

Studies correlating magnesium levels (including those of the serum, erythrocyte, leukocyte, platelet, and hair levels) to fibromyalgia have shown varying results (Table 1).

Some studies showed decreased magnesium levels in several tissue compartments in fibromyalgia patients along with a negative correlation between magnesium levels and the clinical parameters of fibromyalgia. Bagis et al reported significantly lower serum and erythrocyte magnesium levels in patients with fibromyalgia compared to controls, along with a negative correlation between the magnesium levels and fibromyalgia symptoms. In Kasim’s study, serum magnesium levels were significantly lower in patients with fibromyalgia when compared to normal healthy individuals. Kim et al found that concentrations of magnesium in the hair of female patients with fibromyalgia are significantly lower than of controls, even after adjustment of potential confounding factors. Sendur et al reported significantly decreased serum levels of magnesium by fibromyalgia groups along with a meaningful association between magnesium level and fatigue in fibromyalgia patients.

Several reports showed no difference in magnesium levels between fibromyalgia and control subjects, with no correlation between magnesium levels and fibromyalgia parameters. Andretta et al and Sakarya et al found no significant differences in the serum levels of magnesium between fibromyalgia patients and control subjects.

One of the studies performed by Andretta et al showed no correlation between serum magnesium levels and pain, quality of life, and depression risk in the fibromyalgia group. Sakarya et al did not find significant correlations between the mean levels of serum magnesium and number of tender points, scores of visual analog scale (pain intensity measurement), Fibromyalgia Impact Questionnaire (functional status evaluation), and Beck Depression Inventory (depression level assessment) in fibromyalgia patients. The study of Prescott et al also showed no difference in red blood cell or plasma magnesium levels between fibromyalgia patients and controls.

Few investigators reported increased levels of magnesium in patients with fibromyalgia. Bazzichi et al found significantly higher magnesium levels in the platelets of fibromyalgia patients compared to controls. Unlike Kim et al, Ng reported significantly increased hair magnesium levels in fibromyalgia patients.

In some studies, different laboratory assays within the same study showed varying results of magnesium levels. Eisinger et al evaluated leukocyte, erythrocyte, and serum magnesium levels in fibromyalgia patients in comparison to controls. They reported significant increase in leukocyte magnesium level in fibromyalgia patients with slight non-significant decrease in erythrocyte magnesium level and no difference in serum magnesium level, compared to control subjects. Romano et al measured plasma and red blood cell magnesium levels in fibromyalgia patients and compared them with those of osteoarthritis control subjects. They found that fibromyalgia patients, compared to reference laboratory and osteoarthritis controls, had significantly lower red blood cell magnesium levels but no difference in plasma magnesium levels.

Studies Investigating the Effect of Magnesium on Clinical Parameters of Fibromyalgia

Bagis et al investigated the effect of magnesium citrate treatment on fibromyalgia symptoms. The study included
60 premenopausal women diagnosed with fibromyalgia. The patients were divided into 3 groups. The magnesium citrate (300 mg/day) was given to the first group (n = 20), amitriptyline (10 mg/day) was given to the second group (n = 20), and magnesium citrate (300 mg/day) with amitriptyline (10 mg/day) treatment was given to the third group (n = 20). Pain intensity, pain threshold, the number of tender points, the Tender Point Index, the Fibromyalgia Impact Questionnaire, the Beck depression and Beck anxiety scores, and the patient symptoms were evaluated in all the women. All parameters were reevaluated after the 8 weeks of treatment. The number of tender points, Tender Point Index, the Fibromyalgia Impact Questionnaire, the Beck depression and Beck anxiety scores, and the patient symptoms were evaluated in all the women. All parameters were reevaluated after the 8 weeks of treatment. The number of tender points, Tender Point Index, the Fibromyalgia Impact Questionnaire, the Beck depression and Beck anxiety scores, and the patient symptoms were evaluated in all the women. All parameters were reevaluated after the 8 weeks of treatment. The number of tender points, Tender Point Index, the Fibromyalgia Impact Questionnaire, and beck depression scores decreased significantly with the magnesium citrate treatment. The combined amitriptyline with magnesium citrate treatment proved effective on all parameters except numbness, more effective in all measured outcomes than amitriptyline alone (Table 2). The authors suggested that magnesium might have a beneficial effect in patients with fibromyalgia.

Engen et al35 performed a pilot study to collect preliminary data concerning the effect of transdermal magnesium on fibromyalgia patients through a patient questionnaires and survey in a fibromyalgia clinic at a tertiary medical center. The study enrolled 40 female patients with the diagnosis of fibromyalgia; 24 patients completed the study (mean [SD] age, 57.2 [7.6] years; white, 95%; mean body mass index, 31.3 kg/m²). Each participant was provided a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per limb twice daily for 4 weeks. At baseline, week 2, and week 4, participants were asked to complete the Revised Fibromyalgia Impact Questionnaire, 36-Item Short Form Version 2 Health Survey, and a quality-of-life analog scale. The Revised Fibromyalgia Impact Questionnaire sub-scale and total scores were significantly improved at week 2 and week 4. The authors suggested that transdermal magnesium chloride may be of beneficial use in fibromyalgia.

Martínez-Rodríguez et al36 conducted a randomized, controlled trial, to determine the effects of tryptophan and a magnesium-enriched Mediterranean diet on psychological variables and sleep in women with fibromyalgia. The study included 22 women diagnosed with fibromyalgia. Participants were randomly allocated into experimental (EG) and control (CG) groups (EG: Age = 48 ± 4 years old and body mass index [BMI] = 28.2 ± 3.7 kg/m²) (CG: Age = 50 ± 5 years old and BMI = 28.6 ± 5.1 kg/m²). The experimental group received a Mediterranean diet enriched with high doses of tryptophan and magnesium (60 mg of
Table 2. Studies Testing the Effect of Magnesium on Fibromyalgia.

| Investigator                      | Intervention                                                                 | Effect                                                                 |
|-----------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------|
| Bagis et al<sup>24</sup>          | Magnesium (300 mg/day) + amitriptyline (10 mg/day) (n = 20) versus amitriptyline (10 mg/day) (n = 20) | Improvement in VAS, fatigue, sleep, irritability, TP, TPI, dolorimetry score, FIQ, MCGILL, Beck depression, Beck anxiety (P < .05) |
|                                   | Magnesium (300 mg/day) (n = 20) versus magnesium (300 mg/day) (n = 20)      | Improvement in TP, TPI, FIQ, Beck depression (P < .05)                 |
| Engen et al<sup>35</sup>          | Transdermal magnesium chloride solution (n = 24)                            | Improvement in FIQR (P = .001)                                        |
| Martínez-Rodriguez et al<sup>16</sup> | Tryptophan and magnesium enriched mediterranean diet (n = 11) versus standard mediterranean diet (n = 11) | Improvement in trait anxiety, self-image perception, mood state, eating attitudes (P < .05) |
| Gaby<sup>37</sup>                 | Infusions of Myers’ cocktail (magnesium + calcium + B Vitamins + Vitamin C) (n = 30) | Improvement in half of the patients; no parameters specified          |
| Ali et al<sup>39</sup>            | Infusions of Myers’ cocktail (n = 16) versus infusions of lactated Ringer’s solution (placebo) (n = 18) | No difference in TPI, VAS, FIQ, Beck depression score, HSQ            |
| Abraham and Flechas<sup>14</sup> | Magnesium (300-600 mg/day) and malate (1200-2400 mg/day) versus placebo (crossover trial n = 15) | Improvement in TPI (P < .001) and myalgia symptoms                    |
| Russell et al<sup>40</sup>        | Super malic (magnesium [50 mg] and malic acid [200 mg]/tablet) 3 tabs BID versus placebo (crossover trial n = 20) | No difference in VAS, TPI, TPA, HAQ, depression scale score, HSS       |

Abbreviations: FIQ, Fibromyalgia Impact Questionnaire; FIQR; Revised Fibromyalgia Impact Questionnaire; HAQ, Health Assessment Questionnaire; HSQ, Health Status Questionnaire; HSS, Hassle Scale score; MCGILL, McGill Pain Questionnaire; TP, tender point count; TPA, tender point average; TPI, Tender Point Index; VAS, visual analog scale.

Tryptophan and 60 mg of magnesium). The control group received the standard Mediterranean diet. Before and 16 weeks after the intervention, participants completed Pittsburgh Sleep Quality Questionnaire, Body Shape Questionnaire, State–Trait Anxiety Inventory, Profile of Mood States Questionnaire, Eating Attitudes Test-26, and Trait Anxiety Inventory. Significant differences were found between groups after the intervention for the mean scores of trait anxiety, self-image perception, mood disturbance, and eating disorders. The authors concluded that tryptophan and magnesium-enriched Mediterranean diet improve body image satisfaction, mood state, anxiety symptoms, and eating disorders but do not modify sleep quality in women with fibromyalgia.

In a review, Gaby<sup>37</sup> describes his clinical experience with the therapeutic use of intravenous nutrients in fibromyalgia. He gave the modified Myers’ cocktail to about 30 patients with fibromyalgia. The modified Myers’ cocktail consists of magnesium, calcium, B vitamins, and vitamin C. Half of the patients have experienced a significant improvement mostly after 3 or 4 treatments. In his review, Gaby refers to a study that was published only as an abstract in which 86 patients with chronic muscular complaints received intramuscular or intravenous injections of magnesium, either alone or in combination with calcium, B vitamins, and vitamin C, with 74% of the patients demonstrating improvement in their symptoms.<sup>38</sup>

Ali et al<sup>39</sup> devised a randomized, double-blind, placebo-controlled pilot study to assess the feasibility, safety, and provided insights into the efficacy of Myers’ Cocktail. The study included 34 adult fibromyalgia patients. Subjects were randomly assigned either to treatment (weekly infusions of Myers’ Cocktail) or to placebo (weekly infusions of lactated Ringer’s solution) for 8 weeks. Primary outcome was the change in the Tender Point Index, assessed 8 and 12 weeks after initiation. Secondary measures included a visual analog scale to assess global pain, and validated measures of physical function (Fibromyalgia Impact Questionnaire), mood (Beck Depression Index), and quality of life (Health Status Questionnaire 2.0). No statistically significant differences were seen between the treatment and placebo groups, in any outcome measure, at 8 and 16 weeks. The authors concluded that the efficacy of Myers’ Cocktail for fibromyalgia, relative to placebo, remains uncertain.

Abraham and Flechas<sup>14</sup> treated 15 fibromyalgia patients for an 8-week period with a combination of magnesium (300-600 mg) and malate (1200-2400 mg) in a randomized, placebo-controlled, open-label, crossover trial. The treatment group demonstrated improvement in the Tender Point Index scores as well as the myalgia symptoms.

Russell et al<sup>40</sup> assessed the efficacy of Super Malic (contains 200 mg of malic acid and 50 mg of magnesium/tablet, given as 3 tablets twice a day) in treatment of primary fibromyalgia syndrome. The study included 24 participants with primary fibromyalgia. The participants were randomized to compare the combination of malic acid and magnesium to placebo in a 2-period (4 weeks per period), double blinded, cross-over design trial. The 20 participants who completed
the study were analyzed for efficacy through 3 primary and 3 secondary outcome measures. The 3 primary outcome measures assessed pain and tenderness. Measurements included were a patient self-assessment of pain on a 10 cm visual analog scale, the Tender Point Index, and the tender point average. The 3 variables of secondary importance were functional and psychological measures. Variables included the Health Assessment Questionnaire score, the Center for Epidemiologic Studies-Depression Scale score, and the Hassle Scale score. In the blinded trial, there was no significant improvement during the Super Malic treatment period compared to the placebo treatment period.

**Discussion**

Only 0.8% of magnesium is found in the blood (out of which 0.3% is in the serum), with the rest being in the soft tissues, muscles, and bones. Due to the way magnesium is distributed, its concentration in 1 compartment (eg, serum) may not accurately reflect the whole-body magnesium status prompting challenges in determining the magnesium status of the body. Moreover, due to the narrow range of magnesium in the blood that is easily maintained by the exchangeable pool of magnesium, blood magnesium levels can be misleading through masking a deficient magnesium body status. This is reflected in the study of Andretta et al where the mean (±SD) magnesium intake in the fibromyalgia group (132.8 ± 53.76 mg) was significantly lower than the control group (155.52 ± 53.42 mg) (P = .03), yet there was no significant difference in the mean (±SD) serum magnesium level between the fibromyalgia group (2.22 ± 0.14 mg/dL) and the control group (2.2 ± 0.19 mg/dL) (P = .577). Some literature suggests that examining for magnesium retention following a magnesium load is a more sensitive test to determine the body magnesium status compared to simple serum or other body level assays. The challenges in assessing the magnesium status of the tissues have led to inconsistent relationships between magnesium levels and fibromyalgia with some studies showing no difference in magnesium levels between fibromyalgia patients and controls, others showing decreased levels and a few showing increased levels.24–33

In most of the trials that explored the effect of magnesium on fibromyalgia, magnesium was given along with other interventions. Only a few studies used magnesium as a single intervention. Nevertheless, none of these few studies was designed as a blinded randomized controlled study. This adds to the uncertainty about the role of magnesium in fibromyalgia.

**Conclusion**

Our study draws conclusions that are relevant to both clinical researchers and clinicians.

For clinical researchers: Serum and other magnesium levels (including erythrocytes, leukocytes, platelets, and hair magnesium levels) may not reflect the whole-body magnesium status. Utilizing these levels to compare magnesium status of fibromyalgia patients and healthy controls can be misleading. Similarly, employing magnesium levels to assess the effect of magnesium on different parameters of fibromyalgia should be avoided.

For clinicians: Some intervention studies in the literature suggest a benefit from magnesium use in fibromyalgia. Yet this beneficial role is not certain as none of these trials was a blinded randomized placebo-controlled study conducted with magnesium as a single therapy intervention in fibromyalgia.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Michael Boulis https://orcid.org/0000-0001-7420-1305

**References**

1. Bellato E, Marini E, Castoldi F, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. *Pain Res Treat*. 2012;2012:426130. doi:10.1155/2012/426130. Epub 2012 Nov 4. Erratum in: Pain Res Treat. 2013;2013:960270.
2. Mansfield KE, Sim J, Croft P, Jordan KP. Identifying patients with chronic widespread pain in primary care. *Pain*. 2017;158(1):110-119. doi:10.1097/j.pain.000000000000733. Erratum in: Pain. 2017 Jul;158(7):1399.
3. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. *Neuroscience*. 2016;338:114-129. doi:10.1016/j.neuroscience.2016.06.006
4. Centers for Disease Control and Prevention. Fibromyalgia. Centers for Disease Control and Prevention. October 11, 2017. Accessed December 31, 2020. www.cdc.gov/arthritis/basics/fibromyalgia.htm
5. Clauw DJ. Fibromyalgia: a clinical review. *JAMA*. 2014;311(15):1547-1555. doi:10.1001/jama.2014.3266
6. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum*. 2008;58(1):26-35. doi:10.1002/art.23176
7. Arnold LM, Crofford LI, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. *Patient Educ Couns*. 2008;73(1):114-120. doi:10.1016/j.pec.2008.06.005
8. Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. *J Rheumatol*. 2003;30(6):1318-1325.
9. Harth M, Nielson WR. Fibromyalgia and disability adjudication: no simple solutions to a complex problem. Pain Res Manage. 2014;19(6):293-299. doi:10.1155/2014/321307. Erratum in: Pain Res Manag. 2015 Jan-Feb;20(1):56.

10. Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2007;26(4):465-473. doi:10.1007/s10067-006-0433-9

11. Na HS, Ryu JH, Do SH. The role of magnesium in pain. In: Vink R, Nechifor M, eds. Magnesium in the Central Nervous System [Internet]. University of Adelaide Press; 2011. Accessed December 31, 2020. https://www.ncbi.nlm.nih.gov/books/NBK507245/

12. Bjørklund G, Dadar M, Chirumbolo S, Aaseth J. Fibromyalgia and nutrition: therapeutic possibilities? Biomed Pharmacother. 2018;103:531-538. doi:10.1016/j.biopha

13. Romano TJ, Stillier JW. Magnesium deficiency in fibromyalgia syndrome. J Nutr Med. 1994;4(2):165-167. doi:10.3109/1359084940934552

14. Abraham GE, Flechas JD. Management of fibromyalgia: dysfunction of neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;2012:741746. doi:10.1155/2012/741746

15. Weglicki WB, Mak IT, Kramer JH, et al. Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res. 1996;31(5):677-682.

16. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;2012:741746. doi:10.1155/2012/741746

17. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol. 1992;263(3 Pt 2):R734-R737. doi:10.1152/ajpregu.1992.263.3.R734

18. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153-164. doi:10.1111/j.1753-4887.2011.00465.x

19. Workinger JL, Doyle RP, Bortz J. Challenges in the diagnosis of magnesium status. Nutrients. 2018;10(9):1202. doi:10.3390/nu10091202

20. Wall GC, Krypel LL, Miller MJ, Rees DM. A pilot study of complementary and alternative medicine use in patients with fibromyalgia syndrome. Pharm Pract (Granada). 2007;5(4):185-1890. doi:10.4321/s1886-36552007000400008

21. Arranz LI, Canela MA, Rafecas M. Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. Rheumatol Int. 2012;32(9):2615-2621. doi:10.1007/s00296-011-2010-z

22. Wahnerr-Roedler DL, Elkin PL, Vincent A, et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc. 2005;80(1):55-60. doi:10.1016/S0025-6196(11)62958-3

23. Mohabbat AB, Mahapata S, Jenkins SM, et al. Use of complementary and integrative therapies by fibromyalgia patients: a 14-year follow-up study. Mayo Clin Proc Innov Qual Outcomes. 2019;3(4):418-428. doi:10.1016/j.mayocpqo.2019.07.003

24. Bagis S, Karabiber M, As I, et al. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int. 2013;33(1):167-172. doi:10.1007/s00296-011-2334-8

25. Kasim AA. Calcium, magnesium and phosphorous levels in serum of Iraqi women with fibromyalgia. Iraqi J Pharm Sci. 2011;20:34-37.

26. Kim YS, Kim KM, Lee DJ, et al. Women with fibromyalgia have lower levels of calcium, magnesium, iron and manganese in hair mineral analysis. J Korean Med Sci. 2011;26(10):1253-1257. doi:10.3346/jkms.2011.26.10.1253

27. Sendur OF, Tastaban E, Turan Y, Ulman C. The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia. Rheumatol Int. 2008;28(11):1117-1121. doi:10.1007/s00296-008-0593-9

28. Andretta A, Dias Batista E, Madalozzo Schieferdecker ME, et al. Relation between magnesium and calcium and parameters of pain, quality of life and depression in women with fibromyalgia. Adv Rheumatol. 2019;59(1):55. doi:10.1186/s42358-019-0095-3

29. Andretta A, Schieferdecker MEM, Petterle RR, et al. Relations between serum magnesium and calcium levels and body composition and metabolic parameters in women with fibromyalgia. Adv Rheumatol. 2020;60(1):18. doi:10.1186/s42358-020-0122-4

30. Sakarya ST, Akyol Y, Bedir A, Canturk F. The relationship between serum antioxidant vitamins, magnesium levels, and clinical parameters in patients with primary fibromyalgia syndrome. Clin Rheumatol. 2011;30(8):1039-1043. doi:10.1007/s10067-011-1697-2

31. Prescott E, Nørrgård J, Danneskiold-Samsøe B. Fibromyalgia and musculoskeletal pain. Scand J Rheumatol. 1992;21:206. doi:10.3109/03009749209099224. Erratum in: Scand J Rheumatol 1992;21(5):264.

32. Bazzichi L, Giannaccini G, Betti L, et al. ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia syndrome. Clin Rheumatol. 2011;30(8):1039-1043. doi:10.1007/s10067-011-1697-2

33. Engen DJ, McAllister SJ, Whipple MO, et al. Effects of transdermal magnesium chloride on quality of life for patients with fibromyalgia: a feasibility study. J Integr Med. 2015;13(5):306-313. doi:10.1016/S2095-4964(15)60195-9

34. Martinez-Rodriguez A, Rubio-Arias JÁ, Ramos-Campo DJ, et al. Psychological and sleep effects of tryptophan and magnesium-enriched Mediterranean diet in women with fibromyalgia. Int J Environ Res Public Health. 2020;17(7):2227. doi:10.3390/ijerph17072227
37. Gaby AR. Intravenous nutrient therapy: the “Myers’ cocktail”. *Altern Med Rev*. 2002;7(5):389-403.
38. Reed JC. Magnesium therapy in musculoskeletal pain syndromes—retrospective review of clinical results. *Magnes Trace Elem*. 1990;9:330.
39. Ali A, Njike VY, Northrup V, et al. Intravenous micro-nutrient therapy (Myers’ Cocktail) for fibromyalgia: a placebo-controlled pilot study. *J Altern Complement Med*. 2009;15(3):247-257. doi:10.1089/acm.2008.0410
40. Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. *J Rheumatol*. 1995;22(5):953-958.
41. Werbach MR. Nutritional strategies for treating chronic fatigue syndrome. *Altern Med Rev*. 2000;5(2):93-108.
42. Moorkens G, Manuel y Keenoy B, Vertommen J, et al. Magnesium deficit in a sample of the Belgian population presenting with chronic fatigue. *Magnes Res*. 1997;10(4):329-337.